Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy.

ABSTRACT:

Background

Individuals with a loss-of-function single-nucleotide polymorphism in the gene encoding PTPN22 have an increased risk for autoimmune diseases, and patients with cancer with such alleles may respond better to checkpoint blockade immunotherapy. Studies in PTPN22 knockout (KO) mice have established it as a negative regulator of T cell responses in cancer models. However, the role of PTPN22 in distinct immune cell compartments, such as dendritic cells (DCs), remains undefined.

Methods

We developed a novel PTPN22 conditional KO (cKO) mouse model that enables specific deletion in CD11c⁺ DCs by crossing to CD11c-Cre transgenic mice. Antitumor immunity was characterized using the B16.SIY and MC38.SIY cancer models and immune profiles of relevant tissues were ev

SUBMITTER: Acero-Bedoya S 

PROVIDER: S-EPMC11529514 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature